Substance use in individuals at clinical high risk of psychosis

Psychological Medicine

Volumn 45, Issue 11, 2015, Pages 2275-2284

  Buchy, L ^a   Cadenhead, K S ^b   Cannon, T D ^c   Cornblatt, B A ^d   McGlashan, T H ^e   Perkins, D O ^f   Seidman, L J ^g   Tsuang, M T ^c   Walker, E F ^h   Woods, S W ^e   Heinssen, R ⁱ   Bearden, C E ^j   Mathalon, D ^k   Addington, J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c YALE UNIVERSITY   (United States)

^d ZUCKER HILLSIDE HOSPITAL   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h EMORY UNIVERSITY   (United States)

ⁱ NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Alcohol; cannabis; prodrome; substance use; tobacco

Indexed keywords

CANNABIS;

ADOLESCENT; ADULT; CASE CONTROL STUDY; CLASSIFICATION; CLINICAL TRIAL; DISEASE COURSE; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MULTICENTER STUDY; PRODROMAL SYMPTOM; PSYCHOLOGICAL RATING SCALE; PSYCHOTIC DISORDERS; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; SUBSTANCE-RELATED DISORDERS; TOBACCO; YOUNG ADULT;

ADOLESCENT; ADULT; CANNABIS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; PRODROMAL SYMPTOMS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SUBSTANCE-RELATED DISORDERS; TOBACCO; YOUNG ADULT;

EID: 84937023028     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291715000227     Document Type: Article

References (38)

1. Addington J, Addington D (2007). Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatrica Scandinavica 115, 304-309.
2. Addington J, Cadenhead KS, Cornblatt BA, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Addington JA, Cannon TD (2012). North American Prodrome Longitudinal Study (NAPLS 2): overview and recruitment. Schizophrenia Research 142, 77-82.
3. Addington J, Case N, Saleem MM, Auther AM, Cornblatt BA, Cadenhead KS (2014). Substance use in clinical high risk for psychosis: a review of the literature. Early Intervention in Psychiatry 8, 104-112.
4. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 325, 1212-1213.
5. Auther AM, McLaughlin D, Carrion RE, Nagachandran P, Correll CU, Cornblatt BA (2012). Prospective study of cannabis use in adolescents at clinical high risk for psychosis: impact on conversion to psychosis and functional outcome. Psychological Medicine 42, 2485-2497.
6. Barnett JH, Werners U, Secher SM, Hill KE, Brazil R, Masson K, Pernet DE, Kirkbride JB, Murray GK, Bullmore ET, Jones PB (2007). Substance use in a population-based clinic sample of people with first-episode psychosis. British Journal of Psychiatry 190, 515-520.
7. Buchy L, Perkins D, Woods SW, Liu L, Addington J (2014). Impact of substance use on conversion to psychosis in youth at clinical high risk of psychosis. Schizophrenia Research 156, 277-280.
8. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, Seidman LJ, Perkins D, Tsuang M, McGlashan T, Heinssen R (2008). Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Archives of General Psychiatry 65, 28-37.
9. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene x environment interaction. Biological Psychiatry 57, 1117-1127.
10. Clausen L, Hjorthoj CR, Thorup A, Jeppesen P, Petersen L, Bertelsen M, Nordentoft M (2014). Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: a 5-year follow-up study of patients in the OPUS trial. Psychological Medicine 44, 117-126.
11. Compton MT, Kelley ME, Ramsay CE, Pringle M, Goulding SM, Esterberg ML, Stewart T, Walker EF (2009). Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. American Journal of Psychiatry 166, 1251-1257.
12. Cooper J, Mancuso SG, Borland R, Slade T, Galletly C, Castle D (2012). Tobacco smoking among people living with a psychotic illness: the second Australian Survey of Psychosis. Australian and New Zealand Journal of Psychiatry 46, 851-863.
13. Corcoran CM, Kimhy D, Stanford A, Khan S, Walsh J, Thompson J, Schobel S, Harkavy-Friedman J, Goetz R, Colibazzi T, Cressman V, Malaspina D, (2008). Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis. Schizophrenia Research 106, 286-293.
14. Dancey C, Reidy J (2004). Statistics without Maths for Psychology: using SPSS for Windows. Prentice Hall: London.
15. Dragt S, Nieman DH, Becker HE, van de Fliert R, Dingemans PM, de Haan L, van Amelsvoort TA, Linszen DH (2010). Age of onset of cannabis use is associated with age of onset of high-risk symptoms for psychosis. Canadian Journal of Psychiatry 55, 165-171.
16. Dragt S, Nieman DH, Schultze-Lutter F, van der Meer F, Becker H, de Haan L, Dingemans PM, Birchwood M, Patterson P, Salokangas RK, Heinimaa M, Heinz A, Juckel G, Graf von Reventlow H, French P, Stevens H, Ruhrmann S, Klosterkötter J, Linszen DH; EPOS Group (2012). Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. Acta Psychiatrica Scandinavica 125, 45-53.
17. Drake RE, Mueser K, McHugo G (1996). Clinical rating scales. In Outcomes Assessment in Clinical Practice (ed. L. Sederer and B. Dickey), pp. 113-116. Williams and Wilkins: Baltimore.
18. First MB, Spitzer RL, Gibbon M, Williams JBW (1998). Structured Clinical Interview for DSM-IV Patient Edition (SCID-I/P V and SCID-I/NP Version 2. 0). Biometric Research Department: New York.
19. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, Barale F, Caverzasi E, McGuire P (2012). Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Archives of General Psychiatry 69, 220-229.
20. Gill KE, Poe L, Azimov N, Ben-David S, Vadhan NP, Girgis R, Moore H, Cressman V, Corcoran CM (2013). Reasons for cannabis use among youths at ultra high risk for psychosis. Early Intervention in Psychiatry. Published online 26 November 2013. doi:10. 1111/eip. 12112
21. Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM (2008). Gene-environment interplay between cannabis and psychosis. Schizophrenia Bulletin 34, 1111-1121.
22. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, van Os J (2005). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 330, 11.
23. Kolliakou A, Joseph C, Ismail K, Atakan Z, Murray RM (2011). Why do patients with psychosis use cannabis and are they ready to change their use? International Journal of Developmental Neuroscience 29, 335-346.
24. Korver N, Nieman DH, Becker HE, van de Fliert JR, Dingemans PH, de Haan L, Spiering M, Schmitz N, Linszen DH (2010). Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls. Australian and New Zealand Journal of Psychiatry 44, 230-236.
25. Kristensen K, Cadenhead KS (2007). Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Research 151, 151-154.
26. Kuepper R, van Os J, Lieb R, Wittchen HU, Hofler M, Henquet C (2011). Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ 342, d738.
27. Machielsen M, van der Sluis S, de Haan L (2010). Cannabis use in patients with a first psychotic episode and subjects at ultra high risk of psychosis: impact on psychotic-and pre-psychotic symptoms. Australian and New Zealand Journal of Psychiatry 44, 721-728.
28. McGlashan TH, Walsh BC, Woods SW (2010). The Psychosis Risk Syndrome: Handbook for Diagnosis and Follow-up. Oxford University Press: New York.
29. Miller WR, Tonigan JS (1996). Assessing drinkers' motivation for change: the Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES). Psychology of Addictive Behaviors 10, 81-89.
30. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370, 319-328.
31. Phillips LJ, Curry C, Yung AR, Yuen HP, Adlard S, McGorry PD (2002). Cannabis use is not associated with the development of psychosis in an 'ultra' high-risk group. Australian and New Zealand Journal of Psychiatry 36, 800-806.
32. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264, 2511-2518.
33. Ruhrmann S, Schultze-Lutter F, Salokangas RK, Heinimaa M, Linszen D, Dingemans P, Birchwood M, Patterson P, Juckel G, Heinz A, Morrison A, Lewis S, von Reventlow HG, Klosterkotter J (2010). Prediction of psychosis in adolescents and young adults at high risk: results from the Prospective European Prediction of Psychosis Study. Archives of General Psychiatry 67, 241-251.
34. Spencer C, Castle D, Michie PT (2002). Motivations that maintain substance use among individuals with psychotic disorders. Schizophrenia Bulletin 28, 233-247.
35. Stowkowy J, Addington J (2013). Predictors of a clinical high risk status among individuals with a family history of psychosis. Schizophrenia Research 147, 281-286.
36. Thompson A, Nelson B, Yung A (2011). Predictive validity of clinical variables in the "at risk" for psychosis population: international comparison with results from the North American Prodrome Longitudinal Study. Schizophrenia Research 126, 51-57.
37. Thornton LK, Baker AL, Johnson MP, Kay-Lambkin F, Lewin TJ (2012). Reasons for substance use among people with psychotic disorders: method triangulation approach. Psychology of Addictive Behaviors 26, 279-288.
38. Wechsler D (1999). Wechsler Abbreviated Scale of Intelligence. The Psychological Corporation: San Antonio, TX.